Stocklytics Platform
Asset logo for symbol GERN
Geron
GERN68
$4.74arrow_drop_up4.86%$0.22
Penny Stock
Asset logo for symbol GERN
GERN68

$4.74

arrow_drop_up4.86%

Performance History

Chart placeholder
Key Stats
Open$4.71
Prev. Close$4.52
EPS-0.35
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.74B
PE Ratio-
LOWHIGH
Day Range4.58
4.74
52 Week Range1.64
5.34
Ratios
Revenue-
EBITDA Margin %-
EPS-0.35

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Geron (GERN)

Geron Corp (GERN) is a biopharmaceutical company that specializes in the development of innovative therapies for cancer treatments. With a market cap of $X billion, GERN has established itself as a key player in the industry. The company's focus lies in the research and development of therapies that target telomerase, an enzyme involved in the growth and survival of cancer cells. GERN's pioneering approach has gained significant attention and has the potential to revolutionize cancer treatment.
The company's stock price history shows fluctuations over the past few years. However, GERN has consistently demonstrated resilience and perseverance. Despite challenges, GERN has managed to maintain a stable position in the market. Investors trust GERN's potential and recognize the value it brings to the industry.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. John A. Scarlett M.D.
Headquarters
Foster City
Employees
107
Exchange
NASDAQ
add Geron to watchlist

Keep an eye on Geron

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the 52-week high and low for Geron (GERN)?

For Geron (GERN), the 52-week high is $5.34, which is 12.66% from the current price. The 52-week low is $1.64, the current price is 189.02% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is Geron's (GERN) price per share?

The current price per share for Geron (GERN) is $4.74. The stock has seen a price change of $0.22 recently, indicating a 4.87% change. This reflects the stock's recent market performance and investor sentiment.
help

Is Geron (GERN) a growth stock?

Geron (GERN) has shown an average price growth of 0.41% over the past three years. It has received a score of 88 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Geron as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Geron (GERN) stock price performance year to date (YTD)?

As of the latest data, Geron (GERN) has a year-to-date price change of 121.5%. Over the past month, the stock has experienced a price change of 6.28%. Over the last three months, the change has been 5.57%. Over the past six months, the figure is 49.29%. Looking at a longer horizon, the five-year price change stands at 229.17%.
help

Is Geron (GERN) a profitable company?

Geron (GERN) has a net income of -$184.13M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -7.86K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$193.94M. Furthermore, the EBITDA is -$226.77M.
help

What is the market capitalization of Geron (GERN)?

Geron (GERN) has a market capitalization of $2.74B. The average daily trading volume is 7.33M, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media